A randomized, controlled trial of ZMapp for ebola virus infection

New England Journal of Medicine

Volumn 375, Issue 15, 2016, Pages 1448-1456

  Davey, Richard T ^a   Dodd, Lori ^a   Proschan, Michael A ^a   Neaton, James ^a   Nordwall, Jacquie Neuhaus ^a   Koopmeiners, Joseph S ^a   Beigel, John ^a   Tierney, John ^a   Lane, H Clifford ^a   Fauci, Anthony S ^a   Massaquoi, Moses B F ^a   Sahr, Foday ^a   Malvy, Denis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; ZMAPP; AMIDE; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT WITHDRAWAL; VIRAL CLEARANCE; VIRUS LOAD; ADOLESCENT; AFRICA; BAYES THEOREM; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; EBOLAVIRUS; GENETICS; HEMORRHAGIC FEVER, EBOLA; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ADOLESCENT; ADULT; AFRICA, WESTERN; AMIDES; ANTIBODIES, MONOCLONAL; BAYES THEOREM; CHILD; COMBINED MODALITY THERAPY; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; POLYMERASE CHAIN REACTION; PYRAZINES; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84991259720     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1604330     Document Type: Article

References (27)

1. International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56: 271-93.
2. Piot P, Muyembe JJ, Edmunds WJ. Ebola in west Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis 2014; 14: 1034-5.
3. Ebola data and statistics: situation summary. Geneva: World Health Organization, January 20, 2016 (http://apps.who.int/gho/data/view.ebola-sitrep.ebola-summary-20160120?lang=en).
4. Whitehead J, Olliaro P, Lang T, Horby P. Trial design for evaluating novel treatments during an outbreak of an infectious disease. Clin Trials 2016; 13: 31-8.
5. Cox E, Borio L, Temple R. Evaluating Ebola therapies - the case for RCTs. N Engl J Med 2014; 371: 2350-1.
6. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374: 33-42.
7. Yazdanpanah Y, Horby P, van Griensven J, et al. Drug assessment in the Ebola virus disease epidemic in west Africa. Lancet Infect Dis 2015; 15: 1258.
8. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514: 47-53.
9. Jahrling PB, Hensley LE, Barrett K, Lane HC, Davey RT. State-of-the-art workshops on medical countermeasures potentially available for human use following accidental exposures to Ebola virus. J Infect Dis 2015; 212: Suppl 2: S84-90.
10. Dodd LE, Proschan MA, Neuhaus J, et al. Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis 2016; 213: 1906-13.
11. Proschan MA, Dodd LE, Price D. Statistical considerations for a trial of Ebola virus disease therapeutics. Clin Trials 2016; 13: 39-48.
12. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proofof-concept trial in Guinea. PLoS Med 2016; 13(3): e1001967.
13. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2015 (https://cran.r-project.org/bin/windows/base/old/3.2.3/).
14. Crowe SJ, Maenner MJ, Kuah S, et al. Prognostic indicators for Ebola patient survival. Emerg Infect Dis 2016; 22: 217-23.
15. de La Vega MA, Caleo G, Audet J, et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest 2015; 125: 4421-8.
16. Faye O, Andronico A, Faye O, et al. Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study. PLoS Med 2015; 12(12): e1001908.
17. Fitzpatrick G, Vogt F, Moi Gbabai OB, et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Médecins Sans Fronti?res Ebola case management centre, Kailahun, Sierra Leone, June-October 2014. J Infect Dis 2015; 212: 1752-8.
18. Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 2015; 15: 1292-9.
19. Lanini S, Portella G, Vairo F, et al. Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest 2015; 125: 4692-8.
20. Li J, Duan HJ, Chen HY, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis 2016; 42: 34-9.
21. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity. I. Clinical trials. Lancet 2001; 357: 373-80.
22. Fleming TR, Ellenberg SS. Evaluating interventions for Ebola: the need for randomized trials. Clin Trials 2016; 13: 6-9.
23. Lanini S, Zumla A, Ioannidis JPA, et al. Are adaptive randomised trials or nonrandomised studies the best way to address the Ebola outbreak in west Africa? Lancet Infect Dis 2015; 15: 738-45.
24. Cohen J, Enserink M. As Ebola epidemic draws to a close, a thin scientific harvest. Science 2016; 351: 12-3.
25. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531: 381-5.
26. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508: 402-5.
27. De Clercq E. Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol 2015; 93: 1-10.